Abstract
Etintidine HCl is a potent H2 -blocker. The effect of clinical doses of etintidine on the disposition of a single oral dose of propranolol was investigated in 12 normal subjects. This was a double-blind, two-way crossover study. Each subject received etintidine (400 mg) or placebo twice a day with meals for 4 days on two occasions (separated by 4 days). On each occasion, the subjects were fasted overnight on Day 3 and were given an oral dose of Inderal® (40 mg propranolol hydrochloride) 30 min following the administration of the morning dose of etintidine or placebo on Day 4. Blood samples were collected prior to and up to 24 hr following the administration of propranolol. The plasma samples were analyzed for propranolol and 4-hydroxypropranolol by HPLC. Comparison of the pharmacokinetic parameters of propranolol between etintidine and the placebo groups indicates that etintidine significantly increased the AUC0−∞,values (573.5 vs. 146.4 ng·hr/ml, p=0.0001)and prolonged the elimination half-life (4.61 vs. 2.33 hr) of propranolol. Statistical evaluation of the pharmacokinetic parameters of 4-hydroxypropanolol indicates that etintidine also increased the AUC0−24 values (43.8 vs. 16.4 ng·hr/ml, p=0.0028) and prolonged the elimination half-life (4.87 vs. 1.97 hr) of 4-hydroxypropranolol. The data suggest that etintidine, like cimetidine, impaired the elimination of propranolol. Etintidine also protracted the elimination of 4-hydroxypropranolol, an active metabolite of propranolol.
Similar content being viewed by others
References
D. C. Brater, W. M. Meyers, K. A. Dandekar, K. A. Pittman, and W. Peterson. Clinical pharmacology of etintidine in patients with duodenal ulcer.Eur. J. Clin. Pharmacol. 23:495 (1982).
A. Somogyi and R. Gugler. Drug interaction with cimetidine.Clin. Pharmacokin. 7:23–41 (1982).
J. R. Powell and K. H. Donn. The pharmacokinetic basis for H2-antagonist drug interactions: Concepts and implications.J. Clin. Gastroenterol. 5 (Suppl. 1):95–113 (1983).
S. M. Huang, H. S. Weintraub, T. B. Marriott, B. Marinan, R. Abels, and P. T. Leese. Etintidine-theophylline interaction study in humans.Biopharm. Drug Disp. 8:561–569 (1987).
S. M. Huang, E. Rubin, and T. B. Marriott. A high performance liquid Chromatographic microassay employing liquid-solid extraction technique for etintidine in plasma.Pharm. Res. 4:133–136 (1987).
A. J. Barr, J. H. Goodnight, J. P. Sall,et al. SAS User's Guide, SAS Institute, Inc., Raleigh, NC, 1982.
S. M. Huang, H. S. Weintraub, T. B. Marriott, R. Buck, and R. Abels. Comparative oral bioavailability study of etintidine HCl (400 mg base equivalent) from tablet, capsule, and solution formulations.Pharm. Res. 3:118S (1986).
B. K. Park. Prediction of metabolic drug interactions involving β-adrenoceptor blocking drugs.Brit. J. Clin. Pharmacol. 17:3S-10S (1984).
W. Kirch, H. Spahn, H. Kohler, and E. Mutschler. Influence of β-receptor antagonists on pharmacokinetics of cimetidine.Drugs 25(Suppl. 2):127–130 (1983).
J. Feeley, G. R. Wilkinson, and A. J. J. Wood. Reduction of liver blood flow and propranolol metabolism by cimetidine.New Eng. J. Med. 304:692–695 (1981).
A. M. Heagerty, M. A. Donovan, L. M. Castleden, J. F. Pohl, L. Patel, and A. Hedges. Influence of cimetidine on pharmacokinetics of propranolol.Brit. Med. J. 282:1917–1918 (1981).
A. J. J. Wood and J. Feeley. Pharmacokinetic drug interactions with propranolol.Clin. Pharmacokin. 8:253–262 (1983).
G. R. Wilkinson and D. G. Shand. A physiological approach to hepatic drug clearance.Clin. Pharmacol. Ther. 18:377–390 (1975).
P. A. Routledge and D. G. Shand. Clinical pharmacokinetics of propranolol.Clin. Pharmacokin. 4:73–90 (1979).
R. Gomeni, G. Bianchetti, R. Sega, and P. L. Morselli. Pharmacokinetics of propranolol in normal 0healthy volunteers.J. Pharmacokin. Biopharm. 5:183–192 (1977).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Huang, SM., Weintraub, H.S., Marriott, T.B. et al. Etintidine-propranolol interaction study in humans. Journal of Pharmacokinetics and Biopharmaceutics 15, 557–568 (1987). https://doi.org/10.1007/BF01068412
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01068412